Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation
about
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinomaYttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinomaExternal beam radiotherapy for unresectable hepatocellular carcinomaYttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature ReviewA nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosisIncreased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomyRadiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysisPerfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinomaResearch reporting standards for radioembolization of hepatic malignancies.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinomaIdentifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging MarkersRadioembolization for primary and metastatic liver cancer.Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomesAlpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.Transcatheter intraarterial therapies: rationale and overviewExternal beam radiotherapy for unresectable hepatocellular carcinoma.Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.Evaluation of cancer treatment in the abdomen: Trends and advances.Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinomaChemoembolization and radioembolization for hepatocellular carcinoma.Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.Imaging of hepatocellular carcinoma and image guided therapies - how we do it.Treatment of intermediate-stage hepatocellular carcinoma.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.Hepatic imaging following intra-arterial embolotherapy.In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?Intra-arterial therapies for liver cancer: assessing tumor response.Interventional Oncology Service Development.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
P2860
Q24186130-5C6A8314-7475-429E-8950-FBD049ED2A09Q24194017-2D30B70D-E535-4BB3-A479-9C99DFF088C4Q24194024-D2263B0F-12B6-434B-AF35-2413F8C2B381Q26743603-B38A9644-47C9-474E-AD27-394F2C5678A6Q28831507-A963D20C-722A-451B-84DA-9C8B5368C609Q34253205-EF0EEA7F-38C1-49D7-BAF2-27A248153B7BQ34680081-7DCE3818-5899-4DF0-BB75-81E6E21A78C4Q34681150-140CC88E-7250-4CFC-A3C4-027A9C3C531CQ35111887-7A82C959-2DE9-475C-A11C-A8F3DEBBFF2DQ35154103-DA222D79-3A29-4150-B8FC-C59791CF1A44Q35203257-0F7F4DF4-2F46-4AB2-B9E1-480CF329A110Q35537007-EA4C8805-69C9-44D7-A254-06A937D787C7Q35564038-F422AE55-925D-423D-82EA-7A67874A73D7Q35691040-7048BD10-FD8C-4E80-A759-A90DE846BBCAQ35815482-3F7BEE90-3F29-4EF0-AA8D-3CB85E11790FQ35894925-242B9CAE-F68C-4D61-B45A-72DF0555CFD0Q36104314-E7C31955-138B-4393-85D5-1D7A2494EB81Q36299237-3049EDE8-5EB5-46AA-96AC-ACE17DAFDD81Q36481071-D41C01EE-F3A6-4B5F-8251-5B996F81CD53Q36773155-258D32F1-041B-461B-A004-F84E62F1FD65Q36832118-82D2E7B3-A7CB-4B89-92C1-9737B994807AQ37143017-1B3A1C7D-698F-43B6-BCEF-D7BB66EAA05BQ37238192-BF21742A-5F97-48D7-895E-68922A689569Q37253841-F1E98A3F-8687-46F5-8A7A-ED701BE09072Q37348887-1F302D8D-743D-4CF0-BDEE-B5A1833279A0Q37396802-448EF8B4-C479-41FF-96D8-E6F0764136ACQ37680183-6F06FD40-0F30-4989-903C-F824F60E8945Q38236876-72B14C22-8D06-4B28-A0C1-69399233B288Q38265024-16837DDF-2AC4-4B4F-B9AB-C35C7D966082Q38265114-37C924D2-83F0-4BE7-9F67-CCB22DE9F8BEQ38716483-66C70A84-5DE4-4955-A71C-1140800A9AD2Q38984450-62154446-82CB-4D13-9979-E3571C0F236FQ39041266-1AC38940-235D-44B3-A5ED-69AC686B3B19Q39349682-6EC87B0F-D1AE-4B6E-B06A-B11CEB90B914Q40091767-F8E9C6CD-B0B6-4839-9D10-2BCB84B92EEEQ41859517-658445C8-C872-4EB0-B90A-37F69B35E5E5Q42237455-DCA9527D-DC94-4874-A2DE-D3D50AB4D6A3Q43961233-BE9ABE65-3048-40FB-B4A2-CAF449A03A59Q48156557-BCBBAB90-0084-4769-A8D4-3BFC8EE9BADDQ50223119-FAEB3FBA-3BDC-4D5C-B946-8351582A63C6
P2860
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@ast
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@en
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@nl
type
label
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@ast
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@en
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@nl
prefLabel
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@ast
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@en
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@nl
P2093
P2860
P50
P1476
Role of the EASL, RECIST, and ...... iologic-pathologic correlation
@en
P2093
Al B Benson
Frank H Miller
Kent T Sato
Khairuddin Memon
Laura M Kulik
Mary F Mulcahy
Michael Abecassis
Paul Nikolaidis
Ramona Gupta
P2860
P304
P356
10.1016/J.JHEP.2010.10.004
P577
2010-10-23T00:00:00Z